| Identification | Back Directory | [Name]
TPN729 | [CAS]
936951-20-1 | [Synonyms]
TPN729
Udenafil Impurity 10
Xamoterol Impurity 4
Benzenesulfonamide, 3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-methyl-4-propoxy-N-[2-(1-pyrrolidinyl)ethyl]- | [Molecular Formula]
C25H36N6O4S | [MOL File]
936951-20-1.mol | [Molecular Weight]
516.66 |
| Hazard Information | Back Directory | [Uses]
TPN729 is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC50 value of 2.28 nM. TPN729 affects erectile function and it can be used for the research of erectile dysfunction[1]. | [in vivo]
TPN729 (1.25, 2.5 and 5.0 mg/kg; intraduodenal injection, once) increases intracavernous pressure/blood pressure (ICP/BP) with the dose of 5.0 mg/kg at all time points and with the dose of 2.5 mg/kg at 75, 90, 105, and 120 minutes time points[1].
TPN729 (5.0 μg/kg; i.v., once) significantly increases ICP and ICP/BP of male Beagle dogs[1]. | Animal Model: | Male Sprague-Dawley rats with corpora cavernosa complete exposure[1] | | Dosage: | 1.25, 2.5 and 5.0 mg/kg | | Administration: | Intraduodenal (i.d.) injection; 1.25, 2.5 and 5.0 mg/kg, once | | Result: | Dose-dependently increased the maximum intracavernous pressure (ICP) and ICP/blood pressure (BP). |
| [IC 50]
PDE5: 2.28 nM (IC50); PDE6: 45.2 nM (IC50); PDE1: 566 nM (IC50); PDE4: 834 nM (IC50); PDE11: 6090 nM (IC50) | [References]
[1] Wang Z, et al. The selectivity and potency of the new PDE5 inhibitor TPN729MA. J Sex Med. 2013 Nov;10(11):2790-7. DOI:10.1111/jsm.12285 |
|
|